Abstract
Type 2 diabetes mellitus (T2D) is considered one of the main risk factors for cardiovascular diseases (CVD), which are responsible for 80% of the premature mortality of the diabetic population. Among CVD, heart failure is a common complication of T2D, occurring in more than one in 5 patients aged over 65 years. Recently, sodium-glucose cotransporter 2 (SGLT2) inhibitors emerged as promisi…